SCHEMBL3737089

SCHEMBL3737089

COc1c(C=C(C)C(=O)O)c(SC)c(OC)c2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 10/20 0.43
AKR1C3 P42330 1/20 0.42
KDM4E B2RXH2 3/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
IDO1 P14902 1/20 0.39
ALDH1A1 P00352 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MCL1 Q07820 2/20 0.35
BCL2A1 Q16548 2/20 0.35
HTT P42858 1/20 0.34
CYP1A1 P04798 1/20 0.33
CYP1B1 Q16678 1/20 0.33
CA12 O43570 1/20 0.33
CA9 Q16790 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3744482 1.00 APEX1 (0.43) APEX1AKR1C3KDM4ECYP1A2CYP2C9
SCHEMBL3737086 1.00 APEX1 (0.43) APEX1AKR1C3KDM4ECYP1A2CYP2C9
SCHEMBL13080089 0.84 AKR1C3 (0.49) APEX1AKR1C3KDM4ECYP1A2CYP2C9
SCHEMBL3726530 0.84 AKR1C3 (0.49) APEX1AKR1C3KDM4ECYP1A2CYP2C9
SCHEMBL3726535 0.84 AKR1C3 (0.49) APEX1AKR1C3KDM4ECYP1A2CYP2C9
SCHEMBL13080078 0.83 KDM4E (0.35) KDM4ECYP1A2CYP2C9IDO1ALDH1A1
SCHEMBL13080068 0.83 KDM4E (0.35) KDM4ECYP1A2CYP2C9IDO1ALDH1A1
SCHEMBL13080086 0.82 APEX1 (0.36) APEX1KDM4ECYP1A2CYP2C9IDO1
SCHEMBL13080073 0.82 APEX1 (0.36) APEX1KDM4ECYP1A2CYP2C9IDO1
SCHEMBL3745872 0.81 AKR1C3 (0.46) APEX1AKR1C3KDM4ECYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2203161-B1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF UNIV INDIANA RES & TECH CORP (US) 2018-05-09 EP disclosed
US-9089605-B2 Quinone derivatives, pharmaceutical compositions, and uses thereof INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-07-28 US disclosed
US-20100297113-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF PURDUE RESEARCH FOUNDATION 2010-11-25 US disclosed
EP-2203161-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF Indiana University Research and Technology Corporation (US) 2010-07-07 EP disclosed
WO-2009042544-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297113-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF APEX1, NQO1, REV1 APEX1 1/4885AKR1C3 933/4885KDM4E 2642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.